Pfizer taps litigator as new GC

Say hello to Pfizer's new general counsel, Amy Schulman (photo), a top litigator who's served as lead attorney on the company's Celebrex and Bextra cases. A partner at DLA Piper, Schulman specializes in defending companies against big product liability lawsuits. She's a top producer for that firm who earned $5.75 million last year. Schulman, 47, replaces Allen Waxman, who left Pfizer in March for personal reasons; she'll report directly to CEO Jeff Kindler, who's also a lawyer. “Her knowledge of the legal, business and regulatory challenges facing the pharmaceutical industry and her experience tackling large, complex cases make her uniquely qualified to lead Pfizer’s legal team," Kindler said in a statement.

- find Pfizer's release
- see the Wall Street Journal story
- check out the WSJ Law Blog's item

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.